Allergizer, Not Pfizergan: How $16bn In Sales Could Be Worth $160bn
This article was originally published in Scrip
If Pfizer can do for Allergan's products what Sanofi did for Genzyme's and Roche did for Intermune's then its new acquisition may actually pay off – by putting Pfizer ahead in a new pharma game, a game that Allergan knows better.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.